{
    "clinical_study": {
        "@rank": "161596", 
        "arm_group": {
            "arm_group_label": "KD025", 
            "arm_group_type": "Experimental", 
            "description": "KD025 200 mg (two 100 mg capsules) orally once daily for 28 days"
        }, 
        "brief_summary": {
            "textblock": "The primary objective is to assess the safety and tolerability of 200 mg of KD025\n      administered orally once daily for 28 days"
        }, 
        "brief_title": "A Safety and Tolerability Study of KD025 Treatment in Subjects With Moderately Severe Psoriasis Vulgaris", 
        "condition": "Psoriasis Vulgaris", 
        "condition_browse": {
            "mesh_term": "Psoriasis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of moderately severe plaque psoriasis that has been stable for 6 months and\n             has failed at least one line of systemic therapy and is a candidate for additional\n             systemic therapy.\n\n          -  Had a PASI of \u226512\n\n          -  At least 10% of body surface area that is affected by plaque psoriasis.\n\n          -  Willing to avoid tanning devices or sun bathing.\n\n          -  Willing to forgo systemic and topical treatments for psoriasis during the course of\n             the study.\n\n          -  Adequate bone marrow function\n\n          -  Negative urine pregnancy test (for women of childbearing potential)\n\n          -  Agree to use a highly effective method of birth control (< 1% per year failure rate)\n             during the study and for 1 month after the termination of the study.\n\n          -  Willing to complete all study measurements and assessments in compliance with the\n             protocol.\n\n        Exclusion Criteria:\n\n          -  Non-plaque or drug-induced psoriasis\n\n          -  Currently using corticosteroid or immunosuppressive therapy except for Class 5 or\n             weaker topical corticosteroids to the face, groin, or scalp\n\n          -  Using any topical therapy except for the following:\n\n               1. Class 5 or weaker steroids and phototherapy for 4 weeks prior to study entry\n\n               2. Immunosuppressive therapies for 4 weeks prior to study entry\n\n               3. Methotrexate, acitretin, or cyclosporine for 4 weeks prior to study entry\n\n               4. Biologic therapies for 3 months prior to study entry.\n\n          -  Concomitant condition requiring treatment with moderate to high dose steroids in the\n             12 weeks prior to screening.\n\n          -  Viral, fungal, or bacterial skin infection.\n\n          -  Pregnant or lactating woman.\n\n          -  Currently participating in another study with an investigational drug or within 28\n             days of study entry\n\n          -  History or other evidence of severe illness or any other conditions that would make\n             the subject, in the opinion of the investigator, unsuitable for the study\n\n          -  History or presence of any of the following:\n\n               1. Hepatic disease and or alanine aminotransferase (ALT) or aspartate\n                  aminotransferase (AST) > 1.5 \u00d7 the upper limit of normal (ULN) at screening\n\n               2. Renal disease and/or serum creatinine > 1.5xULN at screening\n\n          -  Has QTc(f) intervals of > 450 msec at the screening or pre-dose ECG\n\n          -  Subject is receiving any drugs known to prolong the QTc interval, including any\n             anti-arrhythmic medications within 2 weeks prior to screening\n\n          -  Subject is receiving any drug that is a strong CYP enzyme inhibitor\n\n          -  Subject is receiving any concomitant systemic drug that is metabolized by CYP enzyme\n\n          -  Previous exposure to KD025 or known allergy/sensitivity to KD025 or any other ROCK-2\n             inhibitor."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "8", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 2, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02106195", 
            "org_study_id": "KD025-205"
        }, 
        "intervention": {
            "arm_group_label": "KD025", 
            "intervention_name": "KD025", 
            "intervention_type": "Drug", 
            "other_name": "SLX-2119"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 3, 2014", 
        "location": {
            "contact": {
                "email": "bswasdib@uci.edu", 
                "last_name": "Brian Swasdibutra", 
                "phone": "949-824-2319"
            }, 
            "facility": {
                "address": {
                    "city": "Irvine", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "92697"
                }, 
                "name": "UC Irvine Health, Dept of Dermatology"
            }, 
            "investigator": {
                "last_name": "Jennifer Soung, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 2a, Open-Label Study to Evaluate the Safety and Tolerability of KD025 Treatment in Subjects With Moderately Severe Psoriasis Vulgaris Who Have Failed First-Line Therapy", 
        "other_outcome": [
            {
                "description": "To achieve improvement in PGA", 
                "measure": "Improvement in Physicians Global Assessment (PGA)", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "description": "Change in cytokine expression in punch biopsy after 28 days of treatment with KD025", 
                "measure": "Change In Cytokine Expression", 
                "safety_issue": "No", 
                "time_frame": "28 days"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To evaluate the safety and tolerability of 200 mg of KD025 administered orally once daily for 28 days in subjects with Psoriasis", 
            "measure": "Number of Subjects Experiencing Adverse Events as a Measure of Safety and Tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "28 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02106195"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "To assess the decreases, if any, in PASI in all subjects after 28 days of dosing with 200 mg of KD025", 
            "measure": "Decrease in Psoriasis Area and Severity Index (PASI)", 
            "safety_issue": "No", 
            "time_frame": "28 days"
        }, 
        "source": "Kadmon Corporation, LLC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Kadmon Corporation, LLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}